Focal, or alopecia areata - an autoimmune skin disease, in which on the scalp, the skin of the face and other parts of the body, foci of alopecia are formed.

This common disease in America alone suffers 6.8 million people.

Employees of the Medical Center of Columbia University (USA) declare that preparations from the group of JAK-inhibitors restore hair growth in alopecia areata in 92% of cases.

As is known, in focal alopecia, the immune system of patients attacks hair bulbs, stopping hair growth in affected areas. So there are foci of alopecia.

Patients who lose more than 50% of hair, American doctors have traditionally prescribed systemic therapy (injections and pills), which "distracts" the immune system from hair follicles.

Unfortunately, these drugs do not help every patient.

Researchers from CUMC conducted an open clinical trial in which 12 patients with focal alopecia were prescribed an inhibitor of Janus kinases (JAK).

It is about the drug rusolitinib (ruxolitinib), used in oncohematology.

The results published in the Journal of Clinical Investigation struck Western dermatologists.

As well as the results of a parallel study organized at Stanford and Yale.

JAK-inhibitors stimulate hair growth.

Alopecia areata is the second most common cause of alopecia.

The disease equally affects women and men of all ages.

At the moment there is no method of treatment that can completely restore hair on the affected parts of the body.

Oral JAK-inhibitors became the first hope of patients on the return of hair.

medbe. en.

Keywords:.